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INTRODUCTION 
Stroke is one of the major causes of mortality and morbidity worldwide. 
After coronary artery disease and cancers of all types, stroke is the third 
commonest cause of death worldwide. 
The World Health Organisation (WHO) defines stroke as rapid 
development of clinical signs and symptoms of a focal neurological disturbance 
lasting more than 24 hours or leading to death with no apparent cause other 
than vascular origin (WHO 2015). 
In India, age adjusted prevalence rate of ischemic stroke is 250-
350/1,00,000 and stroke contributes 1.2% of total death in India. As late as 
2000, India was ranked among countries lacking sufficient data on stroke. 
Over 80% of death due to stroke occurs in low-income and middle-
income regions of the world. Identifying  predictors of mortality is important so 
that prompt therapeutic measures could be initiated to improve outcome. 
Early mortality due to stroke is directly related to stroke. Complications 
affect the mortality only later in the course .Previous studies have elucidated 
the various risk factors of stroke as well as the factors which influence 
mortality, which serve as predictors of mortality. Stroke severity, type of 
stroke, increased age, level of consciousness and hyperglycaemia are a few of 
them. These are non-modifiable, hence of limited interest in clinical practise. 
2 
 
Identification of  predictors of mortality which are modifiable are vital so that 
prompt therapeutic measures can be started to improve outcome. 
Albumin is a multi-factorial protein which has been proven to have 
neuroprotective effect in animal studies. Albumin also is an indicator of 
nutritional status. 
Studies on prognostic factors of ischemic stroke in our population are 
limited. Serum albumin level at admission was found to be an independent 
prognostic factor for ischemic stroke outcome in studies done in western 
population. Some of the studies have shown that albumin transfusion is capable 
of minimising volume of infarction and cerebral edema. Albumin reduces the 
hematocrit as well as the erythrocyte sedimentation rate by its affect on 
erythrocyte aggregation. Effect of albumin is primarily in the early reperfusion 
phase of acute ischemic stroke where it has an inhibitory effect on thrombosis, 
stagnation and adhesion of leucocytes in microcirculation. 
There is scarcity of data regarding the usefulness of albumin as a 
prognostic indicator. Hence through this study, the goal is the understand the 
association between serum albumin on admission and the functional status at 
90 days. It also aims to find the other indicators that influence the outcome 
after ischemic stroke. 
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AIMS AND OBJECTIVE 
 
1.  To study whether serum albumin is a good prognostic indicator of acute 
ischemic stroke using modified rankin scale at 3 months follow up of 
patients admitted in general medicine ward, Coimbatore Medical 
College Hospital 
2.  To identify other clinical and biochemical factors affecting the 
prognosis of acute ischemic stroke as measured by modified rankin 
scale at 3 months follow up 
3.  To measure the stroke severity at admission using scandinavian stroke 
scale. 
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REVIEW OF LITERATURE 
Human brain composed of 100 billion neurons forming trillions of 
connection with other brain cells, making it one of the most complex structures. 
The integrative power of the brain is the result of the integrity of these 
connections. Stroke is one disease that has helped us understand the brain in 
greater detail. Different symptoms that occur after a stroke signify the different 
areas that are affected. The disability caused by stroke is because of the 
inability of the brain cells to regenerate. 
Globally about 15 million new stroke events occur every year, two-third 
of which occur in people living in low income and middle income countries. 
Demographic transition resulting from adaptation of westernized lifestyle is 
also likely to increase the burden of stroke in developing economies [1]. 
Ischemic brain stroke is caused by sudden cessation of blood supply to 
the brain, resulting in corresponding neuronal cell death and neurological loss 
of function.[1] Acute Ischemic stroke (AIS) is caused either by a thrombus or 
an embolus resulting in complete occlusion of cerebral vessel. Occlusion and 
vascular cessation damages the concerned brain areas.[1,2] AIS is more 
common than the hemorrhagic brain stroke. Brain stroke is a cause of 
morbidity and mortality. WHO estimates show the brain stroke is second most 
leading cause of mortality next to the ischemic heart disease in the developed 
countries, whereas in poor countries it ranks sixth leading cause.[2] It is crucial 
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to diagnose the acute brain stroke at the earliest as the available drug therapy 
reduces the morbidity and mortality and improves the patient prognosis. 
ANATOMY 
 All the arteries supplying the brain are branches of the brachiocephalic 
arteries arising from the aorta. The common carotid arteries of both sides 
ascend the anterior neck and bifurcate at the level of the angle of mandible 
forming internal and external carotid arteries. The internal carotid artery with 
its tributaries, the middle cerebral artery(MCA) and anterior cerebral 
artery(ACA) forms the anterior circulation which perfuse the entire frontal and 
parietal lobes and most part of temporal lobes. 
Posterior circulation (vertebrobasilar system) is formed form the right 
and left vertebral arteries which are branches of the subclavian artery arising 
from the aorta. They ascend within the vertebral foramen and loop over the 
transverse process of C1 vertebra and enter the skull via foramen magnum. The 
vertebral arteries of both side join to form basilar artery at the level of pons. 
Basilar artery bifurcates at the level of midbrain forming the right and left 
posterior cerebral artery. The vertebrobasilar system with its perforating 
branches perfuse the brain stem , cerebellum, thalamus, occipital lobe and part 
of temporal lobe. 
At the base of brain, the major arteries meet to form the Circle Of Willis 
where the anterior cerebral artery and the middle cerebral artery are linked to 
the posterior cerebral artery by anterior and posterior communicating artery. 
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The anastomosis forms the communication between the anterior and the 
posterior circulation, and between the right and left side of the brain. 
 
 
FIGURE NO. 1- ARTERIAL SUPPLY OF BRAIN: CIRCLE OF WILLIS 
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FIGURE NO.2- VASCULAR TERRITORIES OF THE BRAIN 
 
FIGURE NO.3- FUNCTIONAL AREAS OF THE BRAIN 
8 
 
WHO definition of stroke 
Rapidly developing clinical symptoms or signs of focal or global loss of 
cerebral function with symptoms lasting for more than 24 hours or leading to 
death with no apparent cause other than vascular origin. 
TYPES OF STROKE 
• ISCHEMIC -85% 
• HEMORRHAGIC- 15% 
HEMORRHAGIC STROKE 
TYPES 
• Subdural / Epidural Hemorrhage: produced by trauma 
• Subarachnoid hemorrhage-: due to trauma or rupture of 
intracranial aneurysm 
• Intraparenchymal hemorrhage 
INTAPARENCHYMAL HEMORRHAGE 
• Most common type: intracerebral hemorrhage 
• Causes 
o Hypertension 
o Trauma 
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o Cerebral amyloid amgiopathy 
o Cocaine and amphetamine use(in young) 
o Coagulopathy 
o AV malformation 
o Metastatic brain tumour 
ISCHEMIC STROKE 
ETIOLOGY 
o Thrombosis 
o Large vessel thrombosis 
o Lacunar(small vessel) stroke 
o Dehydration 
o Embolic occlusion 
o Artery to artery 
 Carotid bifurcation 
 Aortic arch 
 Arterial dissection 
o Cardioembolic 
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 Atrial fibrillation 
 Mural thrombus 
 Myocardial infarction 
 Dilated cardiomyopathy 
 Valvular lesion: mitral stenosis 
Mechanical valve 
Infective endocarditis 
o Paradoxical embolus: Atrial septal defect 
   Patent foramen ovale 
o Atrial septal aneurysm 
o Spontaneous echo contrast 
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PATHOPHYSIOLOGY OF ISCHEMIC STROKE  
CEREBRAL BLOOD FLOW 
o Normal cerebral perfusion is about 50-60ml/ 100gm /min15 
Since neurons are incapable of anaerobic respiration, and the 
absence of stored glucose ,the effects of brain ischemia are rapid . In 
response to ischemia, vascular autoregulatory mechanisms come into 
play by local vasodilatation, opening of collaterals and increased 
utilisation of oxygen and glucose from blood. 
o A decrease in cerebral perfusion to zero leads to death of brain tissue 
within 4-10 min. 
o Reduction  to less than 10ml/100gm/min of brain tissue culminates in 
irreversible neuronal injury. 
o A decrease to less than about 16-18ml/100gm/min results in infarction 
within an hour. 
o When blood flow decreases to less than 20ml/100gm/min, an electrical 
silence ensues with a reduction in synaptic activity to preserve energy 
stores. This results in ischemia without infarction, unless this situation is 
extended for several hours or days16. 
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If reperfusion occurs before significant amount of cell death, there 
maybe only transient symptoms ,and this is referred to as transient ischemic 
attack(TIA). The definition of TIA requires all the neurological signs and 
symptoms to resolve within 24 hours regardless of whether there is imaging 
evidence of new permanent brain injury15. 
 Syncope ensues due to a generalised reduction in cerebral blood flow 
due to systemic hypotension. If the reduced blood flow persists longer, 
infarction develops in the border zone of major arterial territories. Severe 
global hypoxia ischemia causes extensive brain damage referred to as hypoxic 
ischemic encephalopathy(HIE).15 
FOCAL  ISCHEMIC  INJURY 
Vascular occlusion due to thrombus or embolus can lead to ischemia of 
the affected vascular territory. At gross tissue level, vascular compromise leads 
to acute ischemia or infarction which is a dynamic process evolving over a 
period of time. At cellular level, hypoxia leads to neuronal injury. 
NEURONAL INJURY 
Ischemia triggers activation of destructive vasoactive enzymes released 
by the endothelium, leucocytes, platelets and other neuronal cells which 
promote the formation of microthrombus which causes occlusion in the 
cerebral microcirculation17. 
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At molecular level, hypoxic ischemic neuronal injury is mainly brought 
about by the overaction of neurotransmitters – glutamate and aspartate. This 
process is called excitotoxicity18. Its onset is triggered by depletion of cellular 
energy stores. Glutamate is normally stored in the synaptic terminals. It is 
cleared from the extracellular space. This causes the opening of calcium 
channels associated with  
N-Methyl-D-Aspartate (NMDA) and Alpha- Amino-3-Hydroxy-5-
methyl-4-Isoxanole propionate (AMPA) receptors. Persistent membrane 
depolarization causes influx of calcium, sodium and chloride ions and efflux of 
potassium ions19. Increase in the intracellular calcium induces activation of 
destructive enzymes like proteases, lipases and endonucleases. These cause the 
release of cytokines and other mediators which ends up destroying the cellular 
integrity20. 
Inflammatory response to tissue damage is mediated by various 
inflammatory mediators , Tumour Necrosis Factor being the key agent. 
Leucocyte recruitment to the ischemic areas occurs within 30 minutes of 
ischemia and reperfusion. Leucocytes cause the activation of vasoactive 
substances like oxygen free radicals, arachidonic acid metabolites (cytokines) 
and nitric acid. These cause vasodilatation, vasoconstriction, increased 
permeability, enhanced platelet aggregation, increased leucocyte adhesion to 
the endothelial wall and immune-regulation.  
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First to respond to hypoxia are endothelial cells. The response is 
morphological, biochemical as well as immunological causing varied 
physiological and pharmacological effects. Endothelial cells swell and form 
microvilli on their luminal surface-this causes a narrowing of luminal patency 
of capillary vessels. As a result, mechanical plugging of the capillaries by 
erythrocytes, leucocytes and platelets ensues21. 
Endothelial cells mediate the action of vasoactive agents like endothelin, 
peptides, eicosanoids; and smooth muscle relaxants such as nitric acid. These 
agents alter the vascular tone of the microcirculation. The key step in the 
initiation of the inflammatory process, leucocyte adherence to the endothelial 
wall, is brought about by activation of endothelial adhesion molecules.  
ISCHEMIC PENUMBRA 
Within about an hour of hypoxic ischemic insult, an oligemic region 
called ischemic penumbra develops around a central core of infarction, where 
the autoregulation is ineffective. In this area, cellular integrity and some 
amount of energy metabolism is preserved. Neurological deficits due to 
worsening of ischemia in this region can be partially or fully reverted by 
reperfusing within a critical time period (2-4hrs) called the Window Of 
Opportunity22. 
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Pathophysiology of the ischemic penumbra is closely related to 
generation of Spontaneous Waves of Depolarisation (SWD). These are 
multifocal in origin, some arising from the core of infarction, and some from 
the ischemic penumbra. They are associated with sustained increase in synaptic 
glutamate and extracellular potassium23. Hypoxic/ rapid depolarisations of the 
neuron supervene just before irreversible neuronal death. 
NEURONAL DEATH 
Occurs by 2 processes-  
Coagulation necrosis 
Apoptosis 
Apoptotic mechanisms start within an hour of ischemic injury whereas 
necrosis sets in about 6hours after arterial occlusion. 
Coagulation Necrosis 
Rapid breakdown of the cellular cytoskeleton primarily due to energy 
failure. due to effects of physical, chemical and osmotic damage to plasma 
membrane. Cell initially swells, then shrinks and undergoes pyknosis over 6-
12hrs. By 24hours, extensive chromolysis has occured resulting in pannecrosis. 
Astrocytes swell and fragment, myelin sheath degenerates16. 
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Apoptosis 
This is programmed cell death. Nuclear damage is the first one to occur. 
Integrity of the plasma membrane and mitochondrial membrane are preserved 
till the end. Prolonged ischemia causes activation of latent suicide proteins in 
the nucleus which triggers the autolytic processes causing  cell death. This 
autolytic process  involves DNA cleavage24. 
Ischemia leads to starvation of the neuron due to lack of glucose and 
oxygen leading on to failure of mitochondria to produce ATP. In the absence of 
energy in the form of ATP, membrane ion pumps stop functioning causing 
depolarisation of neurons and increase in the intracellular calcium. Cellular 
depolarisation also causes increased release of glutamate from the synaptic 
terminals. Excess glutamate activates postsynaptic receptors which enhance the 
neuronal calcium influx resulting in neurotoxicity. Free radicals formed by 
lipid degradation and mitochondrial dysfunction result in catalytic destruction 
of the membrane and damage other vital cell functions. 
Progression and extend of ischemic injury in stroke depends on25 
o Rate of progression and onset- short duration and slow onset strokes are 
better tolerated 
o Collateral circulation- good collateral circulation around the ischemic 
area coorelates with better outcome 
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o  Systemic circulation- constant cerebral perfusion pressure depends on 
adequate systemic blood pressure 
o Haematological factors- hypercoagulability causes exacerbation of the 
vascular occlusion by increasing the progression and extend of 
thrombus. 
o Temperature- increased temperature worsens the ischemic injury 
o Glucose metabolism- hyperglycemia adversely affects size of the infarct 
SUBCLASSIFICTION OF ISCHEMIC STROKE 
LARGE VESSEL ATHEROTHROMBOSIS 
Involves both intracranial and extracranial arteries. 
Atherosclerosis is the most common pathology underlying vascular 
occlusion causing thrombotic stroke26. There is formation of lipid-rich 
atherosclerotic plaques on the inner wall of large vessels. 
They form over a prolonged time course with the effect that the brain is 
able to adjust to the gradual reduction in cerebral blood flow27. Infarcts occur 
only when a critical level of stenosis is reached. These atherosclerotic plaques 
are susceptible to ulceration, thrombosis, calcification, and intraplaque 
hemorrhage and the susceptibility depends on the structure, composition and 
consistency28.. Depending on the vessels involved, location of the lesion within 
the affected vessel, rapidity of development and the presence or absence of 
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anastomoses around the area, it typically ends up in single large territorial 
stroke. 
Most common sites 
- Bifurcation of common carotid artery29 
- Origin of vertebral artery 
- Course of middle cerebral artery prior to bifurcation 
Risk factors- hypertension 
        Diabetes mellitus 
        Dyslipidemia 
EMBOLIC STROKE 
o usually sudden in onset with maximum neurological deficit at the 
onset 
o Non- rheumatic atrial fibrillation is the most common cause of 
cerebral embolism overall, the risk of which is calculated by 
using CHA2DS2VASc score. 
CARDIOEMBOLIC STROKE 
o Occur sue to embolism of thrombotic material on the atrial, ventricular 
or left heart valves. 
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o They usually occur in more than one arterial distribution, mostly 
anterior circulation30. 
o Acute strokes involving the right and left anterior circulation are 
considered embolic unless proven otherwise31. 
o The location and extend of the infarct depends on the extend of 
collateral circulation. 
o The most common causes of cardioembolic stroke are non-
rheumatic/non valvular atrial fibrillation, myocardial infarction, 
prosthetic valves, rheumatic heart disease, and ischemic 
cardiomyopathy. 
o In paradoxical embolism, a venous thrombus migrates into arterial 
circulation through an atrial septal defect or a patent foramen ovale. 
o Other than venous clot- fat emboli, tumour emboli, bacterial 
endocarditis, intravenous air and amniotic fluid emboli can also cause 
paradoxical embolisation. 
ARTERY TO ARTERY EMBOLIC STROKE 
o Thrombus formed on the wall of a particular vessel fragments and sheds 
pieces of clots. These are swept downstream and may lodge in smaller 
branches of the large arteries causing multiple smaller clots within the 
territory of the smaller vessel32. 
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o Most common cause of embolus- carotid bifurcation atherosclerosis 
CAROTID ATHEROSCLEROSIS 
 Most common sites- common carotid bifurcation 
         Proximal internal carotid artery 
 Risk factors- male gender 
        Old age 
        Smoking 
        Hypertension 
        Diabetes 
        Hypercholesterolemia 
 Classified based on degree of stenosis and whether stenosis is 
symptomatic or not. 
INTRACRANIAL ATHEROSSCLEROSIS- produces stroke either by insitu 
thrombosis or embolism. 
DISSECTION OF INTERNAL CAROTID OR VERTEBRAL 
ARTERIES-  
 Trauma 
 Spinal manipulation surgeries 
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 Ehlers danlos type 4 
 Marfan’ syndrome 
 Cystic medial necrosis 
 Fibromuscular dysplasia 
  Neurological outcome of and embolic stroke depends on the affected 
vascular territory and the tendency of the embolus to cause vasospasm by 
acting as a vascular infarct. Vasospasm tends to occur in young patients since 
the vessels are more pliable and less atherosclerotic33. 
Many embolic strokes become hemorrhagic resulting in 
HEMORRHAGIC INFARCT(RED INFARCT)34 where bleed occurs into the 
necrotizing cerebral tissue. Pathogenesis of hemorrhagic infarct is explained by 
2 mechanisms35 
o Reperfusion of the ischemic tissue following spontaneous lysis 
of the embolus. 
o In persistent occlusion of the vessel proximally, due to 
reperfusion from the leptomeningeal vessels that form the 
collateral circulation. 
Probability of hemorrhagic infarction depends on the size of the infarct, 
extent of collateral circulation, and the use of anticoagulant and thrombolytic 
agents. 
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SMALL VESSEL STROKE 
LACUNAR INFARCTION 
o Caused by occlusion of small penetrating arteries 
o Involves the 30-300 micrometer branches of the major cerebral 
arteries that penetrate into the deep gray and white matter of the 
brainstem or cerebellum. 
o Occlusion by atherosclerotic disease or lipohyalinotic thickening 
o Small infarcts 3mm to 2cm diameter causing lacunes 
o Risk factors- Hypertension, age 
o Pure motor stroke- 33 to 50% of all small vessel strokes 
o A large vessel stroke may initially manifest as lacunar syndromes. 
Lacunar syndromes referable to posterior circulation31 
o Hemiballism 
o Hemichorea 
o Isolated dysarthria 
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GLOBAL ISCHEMIA/ HYPOTENSIVE STROKE 
o Occurs following drastic reduction in systolic BP due to any cause. 
o Cerebral gray matter is particularly vulnerable 
o The more susceptible neurons are the Purkinje cell layer of 
hippocampus and Purkinje cell layer of the cerebellar cortex. 
o Abundance of glutamate makes them more susceptible to global 
ischemia. 
o Global ischemia causes maximum damage to areas between the 
territories of the major cerebral and cerebellar arteries called the 
‘Boundary zone’ or ‘Watershed Area’. 
WATERSHED INFARCT 
o Develops in the region between the adjacent arterial territories which 
share a collateral circulation. 
o Parietotemperopccipital triangle at the junction of anterior, middle 
and posterior cerebral arteries is most common affected36. 
o Results in paralysis and sensory loss of the arm sparing the face and 
speech 
o Comprises 10% of ischemic strokes 
o 40% occur in carotid stenosis/occlusion 
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BORDERZONE/TERMINOTERMINAL INFARCTS
37
 
Occurs between two arterial territories whose parent vessels do 
not share a collateral flow. 
STROKE DUE TO UNDERTERMINED CAUSE 
o Includes case where complete workup and screening for cardiac 
conduction/ structural abnormalities, intracranial/ extracranial large 
artery occlusions, coagulopathies and other underlying conditions 
has been inconclusive. 
o Clinical situation where complete workup cannot be done is also 
included in this. 
o Since they form a large share of strokes, newer sub classifications 
like ASCO and computer-aided SSS-TOAST have been proposed to 
study their outcomes and riskfactors38. 
CONDITIONS THAT MIMIC TIA/STROKE 
o Migraine 
o Seizure 
o Hypoglycemia 
o Brain tumor 
o Arteriovenous malformation 
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o Multiple sclerosis 
o Incipient syncope 
o Orthostatic hypotension 
o Cardiac arrhythmia 
o Amnesia 
o Narcolepsy/cataplexy 
o Intracranial inflammation (Meningitis/Encephalitis) 
o Periodic paralysis 
Compressive neuropathy 
o Dizziness of uncertain cause 
o Anxiety 
o Hyperventilation 
o Labyrinthine disease 
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RISK FACTORS FOR STROKE 
o Definite 
• Modifiable :   Cigarette smoking  
                                            Excessive alcohol consumption 
                                            Drug use (cocaine, amphetamines) 
• Non modifiable :  Age 
                                          Sex 
                                          Race 
                                          Familial and genetic factors 
o Possible 
• Oral contraceptive use 
• Diet 
• Personality type 
• Geographic location 
• Season 
• Climate 
• Socioeconomic factors 
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• Physical inactivity 
• Obesity 
• Abnormal blood lipids 
o Disease or disease markers 
 Hypertension 
 Cardiac disease 
 TIA 
 Elevated hematocrit 
 Diabetes mellitus 
 Sickle cell disease 
 Elevated fibrinogen concentration 
 Migraine headaches and migraine equivalents 
 Carotid bruit 
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HYPERTENSION 
o Major risk factor for ischemic stroke 
o Present in 50-70% of cases 
o There is association between blood pressure and risk of 
stroke even at a systolic BP of 115mmHg 
DIABETES 
o Clear risk factor for 1st stroke 
o Independent risk factor for recurrent stroke 
o Predictor of multiple lacunar infarcts  
DYSLIPIDEMIA 
o Increased levels of total cholesterol and LDL-C are 
associated with higher risk of ischemic stroke39 
o High serum triglyceride is independently associated with 
ischemic stroke especially large artery atherosclerotic 
strokes40 
o Reduced HDL-C is also associated with greater risk of 
ischemic stroke 
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SMOKING 
o Major independent risk factor for ischemic stroke 
o Risk of stroke is also increased in exposure to passive 
smoking and tobacco smoke in the environment41. 
o Smoking facilitates atherosclerosis 
o 5years after smoking cessation, stroke risk of ex-smoker is 
equal to that of non-smoker 
ALCOHOL 
o Chronic alcoholism and heavy drinking bear a high risk 
for all stroke subtypes 
o Studies have shown that there is a J shaped association 
between alcohol and ischemic stroke with the effect that 
there is protective effect in light or moderate consumption 
to increased risk in heavy consumption. 
o The protective effect is due to raised HDL, decreased 
platelet aggregation and reduced concentration of plasma 
fibrinogen 
o Increased risk is attributed to alcohol induced 
hypertension, hypercoagulable state, reduced cerebral 
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blood flow and atrial fibrillation or cardioembolism due to 
cardiomyopathy  
o Also plays a role in insulin resistance and metabolic 
syndrome. 
OBESITY 
o Body Mass Index > 30kg/m2 is by itself a risk factor for 
cardiovascular disease 
o Major role in primary prevention 
o There are no studies to support that weight reduction may 
reduce the risk of recurrent stroke. 
PHYSICAL ACTIVITY 
o Exerts beneficial effect on various risk factors for stroke 
o Physical activity reduces blood pressure and weight, 
enhances vasodilatation, improves glucose tolerance and 
promotes cardiovascular health. 
METABOLIC SYNDROME 
o Combination of several physiological abnormalities that 
increase risk of stroke. 
31 
 
o According to American Heart Association criteria, 
metabolic syndrome is recognized when 3 out of 5 features 
are present 
I. Increased waist circumference (>102cm in men 
and >88cm in women) 
II. Increased triglycerides (>150mg/dl) 
III. Decreased HDL-C (<40mg/dl in women and 
<50mg/dl in men) 
IV. Increased blood pressure (systolic >130mmHg or 
diastolic >85mmHg) 
V. Increased fasting blood glucose (>100mg/dl) 
o Research has redefined the syndrome so as to include 
subclinical inflammation and disorders of thrombosis, 
fibrinolysis and endothelial function and theories suggest 
that it may be transmitted genetically42. 
HEART DISEASE 
o The basic pathology being the same, if the coronaries are 
diseased, arteries to the brain are also likely to be affected. 
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o Coronary artery disease, congestive heart failure, left 
ventricular hypertrophy, valvular heart disease and 
arrhythmias are all associated with greater risk of stroke. 
AGE 
o Risk of stroke significantly increases with age 
o The risk of stroke with advancing age cannot be changed; it has a 
prime role in assessing stroke risk and planning preventive 
therapies. 
ORAL CONTRACEPTIVE PILLS 
o Oestrogen promotes blood clotting 
o Low dose oestrogen minimizes the risk 
CAROTID BRUIT 
o Noise due to turbulent flow in a blood vessel (artery) as a 
consequence of narrowing due to atherosclerosis. 
o Associated with a high risk of ischemic stroke. 
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FIGURE NO. 4- ISCHEMIC CASCADE IN THE BRAIN 
 
FIGURE NO.5- CASCADE OF CEREBRAL ISCHEMIA 
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INVESTIGATIONS 
o Basic investigations-complete blood count 
         Erythrocyte sedimentation rate 
         Serum electrolytes 
         Blood urea nitrogen 
         Serum creatinine 
         Blood sugar 
         Urine analysis 
         Serum lipid profile 
o Electrocardiogram 
o Chest xray 
o Coagulation profile- prothrombin time 
           Activated partial thromboplastin time 
o Echocardiogram 
o Imaging studies 
o CT-scan 
 Imaging modality of choice in acute stroke 
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 Early identification or exclusion of hemorrhage 
 Identification of extraparenchymal haemorrhages, 
neoplasm, abscess and other conditions mimicking stroke 
 Infarct may not be seen reliably for 24-48 hours 
 Small ischemic strokes in the posterior fossa are not seen. 
 Small infarcts on the cortical surface are missed 
o CONTRAST ENHANCED CT SCAN 
 Picks up subacute infarcts 
 Allows visualisation of venous structures 
 Highlights the deficits in brain perfusion and shows 
regions of infracted brain as well as ischemic penumbra 
 Carotid disease and intracranial vascular occlusions are 
picked up with CT angiography. 
o MRI scan 
 Reliably detects the extent and location of infarct in all 
areas of brain including posterior fossa and cortical 
surface 
 Less sensitive to detect acute bleed 
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 Diffusion weighted imaging more sensitive for early brain 
infarction 
 MR perfusion studies using Gadolinium contrast pick up 
ischemic penumbra 
 MR angiography detects stenosis of extracranial internal 
carotid arteries and large intracranial arteries with high 
sensitivity 
 MRI with fat saturation visualises extra or intracranial 
arterial dissection 
 After the acute period, MRI clearly defines the extend of 
tissue injury and demarcates areas of old infarction from 
new. 
 Highly sensitive to identify areas of new infarction in 
transient ischemic attack. 
o CONVENTIONAL XRAY CEREBRAL ANGIOGRAPHY 
 Considered gold standard in identifying and quantifying 
stenosis of cerebral arteries due to atherosclerosis. 
 CT angiography of entire head and neck may be used in 
the initial evaluation of stroke. 
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 Also identifies aneurysms, vasospasm, intraluminal 
thrombi, arteriovenous fistula, vasculitis, fibromuscular 
dysplasia and collaterals. 
 Drawbacks 
• Arterial damage 
• Groin hemorrhage 
• Embolic stroke 
• Contrast nephropathy 
 Conventional angiography coupled with endovascular 
techniques is employed in cerebral revascularisation. 
o ULTRASOUND TECHNIQUES 
 B mode ultrasound imaging is coupled with Doppler 
ultrasound for flow assessment(duplex ultrasound) 
• Identifies and quantifies stenosis at origin of 
internal carotid artery. 
 Transcranial Doppler 
• Assesses flow in middle cerebral artery, anterior 
cerebral artery, posterior cerebral artery and 
vertebrobasilar system. 
38 
 
 Combination of MR angiography with these ultrasound 
studies used in evaluating vascular stenosis 
o PERFUSION TECHNIQUE  
 Xenon CT and PET 
• Assess and quantify cerebral blood flow 
• Help in the planning of revascularization surgeries 
 Single photon emission computed tomography(SPECT) 
• Measures relative cerebral blood flow 
 CT perfusion imaging 
• When compared with non contrast CT scan, detects 
ischemia and ischemic penumbra with increased 
sensitivity 
 MR perfusion imaging 
• Demarcates the ischemic penumbra when combined 
with MR diffusion imaging 
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TREATMENT 
Immediate Goal : Ensuring perfusion to the ischemic penumbra 
Later Goals : Minimising disability 
                        Preventing complications 
                        Preventing recurrence 
A. MEDICAL SUPPORT 
o Blood pressure 
 Acute blood pressure lowering controversial as collateral 
blood flow is blood pressure dependent 
 Indications for blood pressure lowering 
• Malignant Hypertension 
• Concomitant myocardial ischemia 
• BP > 185/110mmHg 
• Planning for thrombolytic therapy 
o Fever 
 Detrimental 
 Treated with antipyretics and surface cooling 
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o Serum Glucose 
 Maintained at <180mg/dl 
 Insulin infusion used if necessary 
o Cerebral Oedema 
 Peaks on 2nd or 3rd day 
 Causes mass effect for near 10 days 
 More likely with larger infarcts 
 Treated with fluid restriction and IV mannitol which raise 
serum osmolarity 
 Hypovolemia to be avoided as the resulting hypotension 
may worsen the infarction 
 Trials have shown that hemicraniectomy markedly reduces 
mortality 
 Cerebellar Infarction 
• Even small amounts of cerebellar oedema can severely 
raise the intracranial pressure 
• Cerebellar oedema may directly compress the 
brainstem causing coma and respiratory arrest 
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• Emergency surgical decompression may be required 
• Prophylactic suboccipital decompression of large 
cerebellar infarcts is practiced in stroke centres 
o Infections 
 Pneumonia, urinary tract infection and bedsores are the 
common ones encountered 
 Prevented by avoiding aspiration, physiotherapy and 
prophylactic antibiotics when required 
 Use appropriate antibiotics when needed 
o Deep Vein Thrombosis and Pulmonary Embolism 
Prevented using : 
 Pneumatic compression stockings 
 Subcutaneous heparin 
B. INTRAVENOUS THROMBOLYSIS 
o INDICATIONS 
 Clinical diagnosis of ischemic stroke 
 Onset of symptoms to time of drug administration <3hours 
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 CT scan showing no hemorrhage or oedema of > 1/3rd of 
the MCA territory 
 Age > 18years 
 Consent by the patient or surrogate 
o CONTRAINDICATIONS 
 Sustained BP > 185/110mmHg despite treatment 
 Platelet < 1,00,000 
 Hematocrit < 25% 
 Glucose <50 or >400mg/gl 
 Use of heparin within 48hours and prolonged PTT or 
elevated INR  
 Rapidly improving symptoms 
 Prior stroke or head injury within 3months  
 Prior intracranial hemorrhage 
 Major surgery in preceding 14days 
 Minor stroke symptoms 
 Gastrointestinal bleeding in preceding 21days 
43 
 
 Recent myocardial infarction 
 Coma or stupor 
C. ENDOVASCULAR TECHNIQUES 
o Intraarterial administration of thrombolytic agent  
 For large clots in the major vessels which fail to open with 
thrombolysis 
 Not yet approved by US FDA 
o Endovascular Mechanical Thrombectomy 
Indications : 
 Ineligible or with contraindications to thrombolytics 
 Failed vascular recanalisation with IV thrombolytics 
D. ANTITHROMBOTIC TREATMENT 
• Platelet inhibitors 
o Aspirin is the only antiplatelet drug proved to be 
effective in acute ischemic stroke 
o Use of aspirin within 48hours of stroke onset decreases 
risk of stroke recurrence and mortality. 
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o Abciximab, a glycoprotein IIb/IIIa receptor inhibitor, 
should be avoided in acute stroke as it causes 
intracranial hemorrhage. 
• Anticoagulation 
o The routine use of heparin or other anticoagulation in 
atherothrombotic stroke is not supported by trials. 
E. NEUROPROTECTION 
• Measures that attempt to prolong the brain’s tolerance to 
ischemia  
• Hypothermia 
• Drugs that block excitatory amino acid pathway 
F. STROKE CENTRES 
• A dedicated stroke team improves neurologic outcome and 
reduces mortality. 
• Emergency 24 hour evaluation of patients with acute stroke and 
considering thrombolysis or endovascular treatments 
G. REHABILITATION 
• Includes early physiotherapy as well as occupational, and speech 
therapy. 
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• educating the patient and family about the patients’ neurological 
deficit and on prevention of complications 
• Aims to maximise recovery 
• Restraint therapy: immobilizing the affected side improves 
hemiparesis. 
This shows that physical therapy recruits unused neural pathways and 
the fact suggests that the human nervous system is more adaptable than 
originally thought. 
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ALBUMIN 
 Most abundant plasma protein 
 55-60% of serum protein 
 585 aminoacids which form a single polypeptide chain, with a 
deficiency of tryptophan and methionine residues and an excess of 
charged particles. 
 Molecular weight: 66500Da 
 Xray crystallography reveals tertiary structure of human albumin crystal 
 Heart shaped molecule 80x30 Angstrom 
 Highly flexible molecules which changes shape readily 
 In solution, three domains are arranged in ellipsoid pattern forming low 
viscosity molecule 
 Resilient structure which regains shape easily in physiological 
conditions due to the presence of disulphide bridges 
 Denaturation occurs only in severe nonphysiological changes in 
temperature, pH and chemical environment 
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ALBUMIN METABOLISM 
              Serum albumin concentration depends on the rate of its production and 
degradation and also its distribution in the intravascular as well as the 
extravascular compartments. The total body albumin pool is about 3.5-5kg 
body weight. 42% of this is in the plasma and the rest is in the extravascular 
compartment. A part of this is tissue bound and hence out of circulation. There 
is a daily loss of 120-145g of albumin into the extravascular space, most of 
which is carried back into the circulation by lymphatic drainage. There is an 
intestinal loss of about 1g/day and after digestion, there is reabsorption of 
amino acids and peptides. About 70kg of albumin passes through the kidneys 
everyday, of which a few grams are filtered through the glomerulus. This is 
almost completely reabsorbed and finally only 10-20mg of albumin is lost 
through urine everyday. 
EXTRAVASCULAR POOL OF ALBUMIN 
o Skin, though compromises only 18% of body weight, has 41% of total 
extravascular albumin. 
o Muscle, which forms 45.5% of body weight, contains 40% of 
extravascular albumin. 
o Gut and liver, which constitute 2.8% and 4.1% body weight 
respectively, have 7% and 3% of extravascular albumin respectively. 
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o Subcutaneous tissue, which forms 8% of body weight, contains 9% of 
albumin. 
o Extravascular pool has exchangeable and remote components 
o Albumin escapes into extravascular compartment across capillaries 
o Half of this occurs through continuous capillaries facilitated by an active 
transport mechanism 
o Rate of escape from the circulation depends on the permeability of the 
vessel wall and the hydrostatic and oncotic pressures on both sides of 
the wall (Starling’s law) 
o Albumin binds to the surface receptor- ALBONDIN 
o Albondin is present in most of the capillary beds except in the brain 
o Bound albumin enters the vesicles on the endothelial cell and gets 
released on the interstitial side . 
o Rate of transfer increases on the addition of long chain fatty acids, with 
cationisation and with glycosylation43. 
SYNTHESIS 
o Synthesised only by liver in humans 
o Liver can increase the synthesis to 2-2.7 times the normal 
o Secreted into the portal circulation soon after manufacture 
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o In healthy young adult, rate of synthesis is 194mg/kg/day, about 12-
25gm/day 
o Albumin synthesis requires a suitable nutritional, hormonal and osmotic 
environment 
o Colloid osmotic pressure of the interstitial fluid surrounding the 
hepatocyte regulates  albumin synthesis 
o Requirements for synthesis 
o mRNA for translation 
o adequate supply of amino acids, activated by binding to tRNA 
o ribosomal machinery for assembly 
o energy as ATP or/and GTP 
Factors causing reduced albumin synthesis(table No 1) 
Decreased gene transcription o trauma, sepsis 
o hepatic disease 
o diabetes 
o decreased growth hormone 
o decreased steroids 
Ribosomal disaggregation Decreased nutritional intake 
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A decrease in gene transcription causes decreased mRNA concentration. 
This occurs in acute phase reactions where it is mediated by cytokines mainly 
interleukin-6 and tumour necrosis factor alpha, rate of albumin synthesis is 
controlled by the mRNA concentrations available for action on ribosomes. 
mRNA content is decreased in trauma and diseases processes. Decreased gene 
transcription is also seen in hepatoma cells and in hepatocytes damaged by 
carbon tetrachloride 
Albumin synthesis requires insulin . Decreased synthesis in diabetes 
improves the insulin supplementation. Growth hormone stimulates gene 
transcription in hepatocytes44. 
Steroids have a complex role on albumin synthesis. Combination of 
steroids with insulin or aminoacids causes increased synthesis. But steroids 
also cause increased albumin catabolism. 
Fasting reduces albumin production and protein restriction decreases it 
all the more. In the early phase of protein deprivation, the disintegration of free 
and bound polysomes can be reversed by refeeding with aminoacids -equally 
tryptophan with ornithine. Tryptophan is incorporated into albumin, but 
ornithine is not. Prolonged protein deprivation causes a 50-60% decrease in the 
concentration as well as activity of mRNA. Energy is more important than 
aminoacids under normal circumstances for polysome aggregation. Reduced 
synthesis in starvation is found to correct with glucose refeeding alone which 
causes polysome reaggregation. 
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DEGRADATION 
o total daily albumin degradation is 0.2g/kg/day 
o this constitutes 5% of daily whole body protein turnover 
Most of the organs of the body are involved in the breakdown f albumin. 
40-60% of albumin is broken down by muscles and skin. 10% leaks into 
gastrointestinal tract via stomach wall. Kidneys are responsible for another 
10%. Though the liver has a high rate of metabolism, it degrades less than 
15%. 
Endothelial surface membrane scavenger receptors,gp18 and gp30 bind 
to altered , denatured albumin. This is taken up by the endocytic vesicles which 
fuse with the lysosomes in the endothelial cells. Cell modification of the 
circulating albumin is a signal for receptor-linked lysosomal degradation. 
Chemical modification may also prevent degradation. it is protected 
from breakdown by the binding of long chain fatty acids to albumin, in 
hypoalbuinemia, the ratio of long chain fatty acids to albumin increases and 
breakdown is suppressed. 
The final products of degradation are amino acids. These join the amino 
acid pool inside the cells and in the plasma. 
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FUNCTIONS OF ALBUMIN 
A. MAINTAINING ONCOTIC PRESSURE 
Albumin has higher concentration in plasma than other plasma proteins, 
it has a molecular weight of 66.5kDa. Though this is less than the average 
weight of globulin(147kDa), albumin has great osmotic impact. Because of 
the higher molecular weight and plasma concentrations, in health, albumin 
contributes 80% of the normal oncotic pressure.60% of this is due to the direct 
osmotic effect. Negative charges of the molecule is responsible for the 
remaining 40%, this negative charge is responsible for the attractive force that 
leads to intravascular retention of positively charged solute particles(Gibbs-
Donnan effect). 
Albumin, because of its large extra vascular pool, solubility in water and 
net negative charge, has a major role in the regulation of tissue fluid 
distribution. 
B. BINDING OF SUSTANCES 
Albumin has a structure that can incorporate several different 
substances. Also the structure is flexible and bound substances can be buried 
within its structure. The charge of the binding substances and the strength of 
binding have no correlation. 
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o Substances that bind most strongly to albumin: medium-sized 
hydrophobic organic anions – long chain fatty acids, bilirubin, 
hematin 
o Substances that bind specifically but with less affinity : 
Ascorbate, tryptophan 
o Chirality of the substance also determine the strength of binding 
o Divalent cations like calcium and magnesium bind, but 
monovalent cations  do not 
o Basic drugs tend to bind to albumin 
o Endogenous substances that bind to albumin: eicosanoids, 
copper, zinc, folate, aquacobalamin, bile acids 
o Secondary or tertiary carrier for substances with specific binding 
protein: 
Steroids, vitamin D, Thyroxine 
Drug Binding 
 Binding of the drug to albumin affects its delivery to tissue and also its 
metabolism and eliminations. This also determines the free serum 
concentration of the drug. Highly bound drugs have less concentration of their 
free form in serum. Drug-albumin interactions are responsible for the wide 
inter-individual variations in response to drugs. Factors like age, temperature, 
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Ph and ionic strength influences the drug-albumin interactions. These alter the 
number of functional binding site and thereby the distribution, pharmacological 
action, metabolism and excretion of the displaced drug are altered. 
Binding sites on albumin are broadly classified into site I and site II. 
Site I: along the long loop of subdomain IIa, extending into the shorter loop. 
 Drugs binding to this site: salicylates, werfarin, phenylbutazone, 
indomethacin, digitoxin, furosemide, phenytoin, chlorpropamide, pencillins, 
dyes like sulfobromophthalein, iophenoxate, Methyl red, Evans blue, 
bromocresol green, Biliurubin 
Site II : hydrophobic pocket of residues in subdomain IIIa 
 Substances binding to this site: L-Tryptophan,thyroxine, chloride, 
medium-chain fatty acids, diazepam, bendodiazepine, ibuprofen, naproxen, 
clofibrate 
C. METABOLIC FUNCTIONS 
 Albumin causes the inactivation of certain compounds like disulfiram, 
penem group of antibiotics etc. Because of the avidity of binding, albumin has 
a role in the metabolism of substances like lipids and eicosanoids. Albumin 
stabilises eicosanoids like prostaglandin I2 and thromboxane A2. It also releases 
arachidonic acid from macrophages and favours lipoxygenases activity over 
that of cycloxygenase. 
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Penicillin allergy is due to irreversible coupling of penicilloyl groups to lysine 
group in site 1. This causes production of antibodies to drug-albumin complex. 
D. ACID-BASE FUNCTION 
Albumin acts as an effective buffer by its relative abundance in plasma 
as well as the presence of charged residues on the molecules. At physiological 
pH, albumin contributes to half the normal anion gap with a net negative 
charge of 19. A decrease in serum albumin of 1g/dl increases the standard 
bicarbonate by 3.4mmol/L , thereby causing a reduction in the anion gap by 
3mmol/L. 
E. ANTIOXIDANT FUNCTION 
 Albumin has antioxidant properties under physiological conditions. It 
scavenges the free radicals which are involved in the pathogenesis of various 
diseases. The production of oxygen free-radicals by activated 
polymorphonuclear leucocytes from the enzyme myeloperoxidase is also 
inhibited by physiological solutions of human albumin. This action is due to 
the sulfhydrl groups on albumin. 
F. MAINTAINING MICROVASCULAR INTEGRITY 
 Albumin controls the stress-induced increase in capillary permeability. 
This action is brought about by the endothelial cells which alter the 
permeability of the capillary membrane by tweaking the nature and 
distributions of glycoprotein in the vessel wall. This may be due to the negative 
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charge of the molecule or the reduction in the size of channels by the albumin 
molecule. Albumin prevents the apoptosis of endothelial cells, the peak action 
being at physiological concentrations. 
Albumin slows the onset and enhances the vasodilatory response to 
nitric oxide. Nitric oxide by binding to the sulfhydryl groups of albumin, forms 
the S-nitrosothiol group which is not rapidly degraded. Thus albumin plays a 
role in the regulation of vasodilatory tone of vessels. 
G. ANTICOAGULANT EFFECTS 
 Has a heparin-like action due to resemblance in the structure of 
molecules with plenty of negatively charged groups. Heparin exerts its 
anticoagulant effect by negatively charged sulphate groups to the positively 
charged groups on antithrombin III. Albumin enhances the neutralisation of 
factor Xa by anithrombin III. This explains the negative correlation between 
albumin concentration and heparin requirements in patients on hemodialysis. 
This might also explain the hypercoagulable state occurring in nephrotic 
syndrome. Albumin also exerts an inhibitory effect on platelet aggregation both 
dependant and independent of the cycloxygenase system. 
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FIGURE NO.6- STUCTURE AND BINDING SITES ON ALBUMIN 
MOLECULE 
ANALBUMINEMIA 
 Albumin has large number of variants , about 100, based on the 
electrophoretic mobility. Only one variant, which has high affinity for 
thyroxine, is known to affect the function of albumin, thereby causing Familial 
Dysalbuminemic Hyperthyroidism46. 
 Analbuminemia has also being defined as serum albumin concentration 
of less than 1g/litre. There is a small amount of albumin in circulation which is 
adequate under normal conditions. But in times of stress, when the 
requirements shoot up, features manifest. It is a rare condition which may be 
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sporadic or familial . if familial, it has autosomal recessive inheritance. 
Albumin gene is present, but genetic mutations produce effects which prevent 
translation. 
Cases usually present in adulthood. The features are: 
o Peripheral oedema 
o Lipodystrophy causing lower limb obesity 
o Fatigue 
o Hyperlipidemia without atherosclerosis 
o Reduced osmotic pressure 
o Decrease in arterial pressure causing increased rennin and 
aldosterone concentrations. 
Body tries to compensate for the low serum albumin by slowing the 
rate of degradation. 
ALBUMIN IN CRITICAL ILLNESS 
 Critical illness brings about changes in the distribution and metabolism 
of albumin. 
CHANGES IN DISTRIBUTION 
 There is alteration in the distribution of albumin between the 
intravascular compartment and the extravascular compartment. The underlying 
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pathology is an increased capillary leakage. There occurs endothelial 
dysfunction, causing capillary leakage and loss of proteins, inflammatory cells 
and large volumes of fluid into the interstitial space. The mediators of this 
process are:  
o Endotoxins of gram-negative bacteria 
o Cytokines-TNF-alpha and IL-6 
o Leukotriene and prostaglandins 
o Complement components –C3a and C5a 
o Vasoactive peptides like bardykinin and histamine 
o Chemokine like macrophage inflammatory protein 1alpha 
This altered distribution is predominantly seen in sepsis and after major 
surgical stress. The trans-capillary escape rate increases upto 300% in septic 
shock and by 100% after cardiac surgery. In sepsis, this improves with 
appropriate treatment. When albumin moves out of the vascular compartment, 
there is a resultant increase in lymphatic flow intravascularly. There is a 30% 
reduction in the total circulating and total exchangeable albumin pools 
following major surgery. This is mainly due to sequestration of albumin in non-
exchangeable sites , for example-wounds, intestine and extra-abdominal sites. 
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CHANGES IN METABOLISM 
 There occurs alteration in the synthesis and degradation of albumin 
resulting in a dramatic decrease in serum albumin concentrations even early in 
the course of a critical illness47. 
Synthesis 
 In trauma, inflammation or sepsis, the acute phase response involves an 
increase in the gene transcription rate of positive acute phase proteins like C-
reactive protein and a decreased rate of albumin synthesis. The decreased 
synthesis is due to reduced gene transcription which is mediated by IL-6 and 
TNFalpha. A sustained inflammatory response results in prolonged inhibitions 
of albumin synthesis. 
Catabolism 
 The degradation rate is mass dependent. So when serum albumin 
concentration decreases, degradation rate also decreases. But in increased 
transcapillary escape of albumin, there is an increase in degradation rate. 
Vascular endothelium is thought to play a major role in the degradation of 
albumin. More of tissue exposure in the presence of increased capillary 
permeability may increase catabolism. But in myxoedema, though there is an 
expansion in the extravascular pool of albumin, there is decreased degradation 
which could be due to the tissue exposure and trapping which protects the 
albumin from degradation. 
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 There is a huge difference in the kinetics of intravenous albumin 
between critically ill and healthy subjects. The point of interest in this aspect is 
that increasing the intravascular albumin concentration using exogenous 
albumin may be beneficial in critical illness. 
 Oncotic pressure is low in patients who are critically ill and this may be 
associated with increased mortality and morbidity. There are arguments that 
supplementation of albumin can increase the oncotic pressure and thereby 
avoid life threatening complications like pulmonary oedema. At the same time, 
there are studies which suggest that pulmonary dysfunction in sepsis is 
independant of oncotic pressure. 
 Drug-albumin interactions are altered in critical illnesses. In renal 
failure, there is accelerated loss of albumin through damaged glomeruli. The 
binding of drugs to albumin is also altered in renal failure, probably by 
alteration in the pH and the accumulation of substances which compete with 
drugs for the binding sites. This results in increased free fraction of drugs 
causing enhanced drug effect in renal failure. Thus it becomes necessary that 
the free serum levels of drugs should be monitored in renal failure in order to 
avoid toxicity. 
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PROGNOSTIC VALUE OF SERUM ALBUMIN 
 Serum albumin acts as an independent predictor of mortality in various 
clinical settings. Serum levels of albumin may also serve as a marker of 
subclinical disease in elderly patients. Studies in hospitalised patients have 
revealed that low serum concentration of albumin is associated with prolonged 
hospital stay, more complications and higher mortality. It also correlates with 
the prolongation of stay in intensive care unit, increased ventilator 
requirements and escalating rate of infections. The daily trend of serum 
albumin may be used as a guide to predict the weaning capability of patients on 
mechanical ventilation48. Serum albumin values at 24-48hours of ICU 
admission were found to be as good as APACHE II score in predicting 
mortality. APACHE III system takes serum albumin value into consideration 
and has better predictive value for mortality in critical illness49. Serum 
albumin, though considered a measure of nutrition, is not a reliable marker of 
the nutritional status in those who are critically ill.  
INTRAVENOUS ALBUMIN THERAPY 
There is no proven benefit for intravenous albumin over other colloids 
in volume replacement in critically ill patients. 
 Serum albumin has a beneficial role in burns patients. In the first 24 
hours, there is a gross increase in capillary permeability with marked 
transcapillary fluid shifts. Beyond 24 hours, intravenous albumin promotes 
reabsorption of plasma. According to the Guidelines Of The Consensus 
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conference in Paris50,  burns less than 15% of body surface area do not require 
albumin. Those involving more than 50% of body surface area require albumin 
right from the start of treatment. For those in between, albumin 
supplementation can wait 24 hours. 
 Albumin therapy is also beneficial in cirrhotic patients with ascites who 
require paracentesis. Post-paracentesis circulatory dysfunction which is the 
increased plasma rennin activity 6 days after paracentesis is prevented by 
albumin therapy. 
LIMITATIONS 
o Injudicious use can cause fluid overload due to plasma expansion. 
o Myocardial depression probably due to binding of calcium ions. 
o Allergic reactions- mostly to contaminants in solution or polymers 
formed during storage 
o Viral transmission though unlikely due to prolonged heat treatments 
during preparation51, there is theoretical risk of Creutzfield- Jakob 
disease. 
o Expensive 
More of research and interventional studies are required and several 
controversies to be cleared before albumin therapy becomes an accepted 
treatment modality to reduce mortality in critically ill patients. 
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MATERIALS AND METHODS 
This observational study was conducted in Coimbatore medical college 
over a period of one year from july 2017 to june 2018. Approval was obtained 
from the Ethics Committee, Coimbatore medical college. 
The study population consisted of 100 patients who got admitted in 
medical wards of our hospital with first instance of ischemic stroke within the 
first 72 hours of onset of symptoms. These patients were included in the study 
after getting informed consent either from the patient or from the legal 
guardian. 
Study design- longitudinal study 
Exclusion criteria: 
• Acute haemorrhagic stroke, ischemic stroke with hemorrhagic 
transformation or stroke related to intracranial space occupying 
lesion (ICSOL). 
• Past history of stroke 
• Patients presenting more than 72 hr after the onset of stroke 
• Patients with diagnosed malignancy 
• Patients with history of chronic liver disease, chronic heart 
failure, chronic kidney disease or dementia 
• Patients with fever or infections 
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Inclusion criteria 
• Patients admitted in medical wards with clinical diagnosis of first 
onset acute ischemic stroke 
• Clinical diagnosis confirmed by CT scan 
• Informed consent to participate in the study 
Cases where defined as per WHO definition of stroke. Hypertension was 
documented  if there were records proving it  or when at least 2 readings of 
blood pressure - systolic blood pressure was ≥140 mm Hg and diastolic blood 
pressure was ≥90 mmHg  after the acute phase of stroke. Coronary artery 
disease was diagnosed with either ECG changes or previous records. Patient 
was considered a smoker if he had a history of smoking in the past 5 years. 
About 243 consecutive patients who were admitted in the medical wards 
with first ever attack of stroke were screened to get the study population of 
100. A detailed history was elicited from the attenders, followed by general 
examination, an elaborate CNS examination and relevant examination of other 
systems. Vitals were stabilised, and patients underwent a CT scan of the brain- 
in order to rule out hemorrhagic stroke or any mass lesion. Severity of stroke 
was graded using the Scandinavian Stroke Scale(SSS). Basic investigations like 
complete hemogram-including ESR, blood sugar, renal function test, liver 
function test and serum proteins-albumin and globulin, lipid profile and urine 
routine examination.ECG was taken to establish any coronary artery disease. 
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 Those that fell under exclusion criteria were excluded. Treatment was 
initiated and carried out according to the institution guidelines. 
Serum albumin was measured using Bromocresol Green. 
Patients were followed up, and after 90 days following the onset of 
stroke, were evaluated either in person or over the phone using the Modified 
Ranking scale to assess their functional status. 
The collected data was entered into Microsoft Excel spreadsheet and 
analysed statistically .The significance of association was tested using Anova 
and Kruskal wallis test. Statistical analysis was carried out to establish whether 
a statistically significant association exist between serum albumin level on 
admission and the stroke severity, as well as the functional outcome at the end 
of 90 days.  The secondary outcomes that were aimed to be tested included the 
association with risk factors and the viability of the stroke scales. 
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RESULTS 
TABLE NO 2: DISABILITY BASED ON MRS SCORE 
DISABILITY (MRS SCORE) NO OF PATIENTS PERCENTAGE 
MILD 23 23% 
MODERATE 23 23% 
SEVERE 29 29% 
DEATH 25 25% 
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TABLE NO 3:AGE DISTRIBUTION 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 40 13 13% 
41-50 22 22% 
51-60 24 24% 
61-70 20 20% 
> 70 21 21% 
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TABLE NO 4: AGE VS DISABILITY 
DISABILITY (MRS SCORE) 
AGE IN YEARS 
MEAN SD 
MILD 61.87 13.48 
MODERATE 52.39 13.8 
SEVERE 58.9 15.34 
DEATH 57.24 13.2 
ANOVA 
P VALUE - 0.144 
NON SIGNIFICANT 
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TABLE NO 5:SEX DISTRIBUTION 
 
SEX NO OF PATIENTS PERCENTAGE 
MALE 54 54% 
FEMALE 46 46% 
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TABLE NO 6: SEX VS DISABILITY 
 
DISABILITY (MRS SCORE) 
SEX 
MALE FEMALE 
MILD 14 9 
MODERATE 12 11 
SEVERE 15 14 
DEATH 13 12 
KRUSKAL WALLIS TEST 
P VALUE - 0.904 
NON SIGNIFICANT 
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TABLE NO 7:PREVALENCE OF SYSTEMIC HYPERTENSION 
 
SYSTEMIC HYPERTENSION NO OF PATIENTS PERCENTAGE 
PRESENT 57 57% 
ABSENT 43 43% 
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TABLE NO 8: SYSTEMIC HYPERTENSION VS DISABILITY 
DISABILITY (MRS SCORE) 
SYSTEMIC HYPERTENSION 
PRESENT ABSENT 
MILD 12 11 
MODERATE 14 9 
SEVERE 18 11 
DEATH 13 12 
KRUSKAL WALLIS TEST 
P VALUE - 0.821 
NON SIGNIFICANT 
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TABLE NO 9: PREVALENCE OF TYPE 2 DIABETES MELLITUS 
 
TYPE 2 DM NO OF PATIENTS PERCENTAGE 
PRESENT 27 27% 
ABSENT 73 73% 
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TABLE NO 10: TYPE 2 DIABETES MELLITUS VS DISABILITY 
 
DISABILITY (MRS SCORE) 
TYPE 2 DM 
PRESENT ABSENT 
MILD 8 15 
MODERATE 8 15 
SEVERE 5 24 
DEATH 6 19 
KRUSKAL WALLIS TEST 
P VALUE - 0.403 
NON SIGNIFICANT 
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TABLE NO 11: PREVALENCE OF OTHER CO MORBIDITIES 
OTHER DISEASES (N=18) NO OF PATIENTS PERCENTAGE 
CAD 8 44% 
DYSLIPIDEMIA 11 61% 
RHD 2 11% 
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TABLE 12: DISABILITY VS OTHER COMORBIDITIES 
DISABILITY (MRS SCORE) 
OTHER DISEASES 
PRESENT ABSENT 
MILD 3 20 
MODERATE 3 20 
SEVERE 9 20 
DEATH 3 22 
KRUSKAL WALLIS TEST 
P VALUE - 0.194 
NON SIGNIFICANT 
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TABLE 13: PREVALENCE OF ADDICTIVE HABITS 
 
ADDICTION (N=32) NO OF PATIENTS PERCENTAGE 
SMOKING 26 81% 
ALCOHOL 9 28% 
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TABLE NO 14: DISABILITY VS ADDICTION 
 
DISABILITY (MRS SCORE) 
ADDICTION 
PRESENT ABSENT 
MILD 9 14 
MODERATE 7 16 
SEVERE 8 21 
DEATH 8 17 
KRUSKAL WALLIS TEST 
P VALUE - 0.844 
NON SIGNIFICANT 
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TABLE NO 15:TYPE OF LESION 
TYPE OF LESION NO OF PATIENTS PERCENTAGE 
MCA INFARCT 52 52% 
MULTI INFARCT 19 19% 
POST CIRCULATION STROKE 4 4% 
LACUNAR INFARCT 25 25% 
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TABLE NO 16: DISABILITY VS TYPE OF LESION 
DISABILITY 
(MRS SCORE) 
TYPE OF LESION 
MCA 
INFARCT 
MULTI 
INFARCT 
POSTERIOR 
CIRC 
STROKE 
LACUNAR 
INFARCT 
MILD 14 3 0 6 
MODERATE 9 6 2 6 
SEVERE 14 7 0 8 
DEATH 15 3 2 5 
KRUSKAL WALLIS TEST 
P VALUE - 0.509 
NON SIGNIFICANT 
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TABLE NO 17:GLASGOW COMA SCALE ON PRESENTATION 
GLASGOW COMA SCALE NO OF PATIENTS PERCENTAGE 
MILD (12-15) 12 12% 
MODERATE (9-12) 45 45% 
SEVERE (<9) 43 43% 
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TABLE NO 18: DISABILITY VS GLASGOW COMA SCALE 
 
DISABILITY (MRS SCORE) 
GLASGOW COMA SCALE 
MILD MODERATE SEVERE 
MILD 11 12 0 
MODERATE 1 18 4 
SEVERE 0 15 14 
DEATH 0 0 25 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE NO 19:SCANDINAVIAN STROKE SCALE(SSS) SCORE ON 
PRESENTATION 
 
SCANDINAVIAN STROKE SCALE NO OF PATIENTS PERCENTAGE 
MILD (43-58) 6 6% 
MODERATE (26-42) 36 36% 
SEVERE (0-25) 58 58% 
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TABLE 20: DISABILITY VS SSS SCORE 
 
DISABILITY (MRS SCORE) 
SCANDINAVIAN STROKE SCALE 
MILD MODERATE SEVERE 
MILD 6 17 0 
MODERATE 0 12 11 
SEVERE 0 7 22 
DEATH 0 0 25 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE NO 21: DISABILITY VS SERUM ALBUMIN 
DISABILITY (MRS SCORE) 
SERUM ALBUMIN 
MEAN SD 
MILD 4.24 0.27 
MODERATE 4.05 0.42 
SEVERE 3.31 0.65 
DEATH 2.9 0.51 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE NO 22: SSS SCORE VS SERUM ALBUMIN 
 
SCANDINAVIAN STROKE SCALE 
SERUM ALBUMIN 
MEAN SD 
MILD 4.2 0.45 
MODERATE 3.9 0.65 
SEVERE 3.34 0.68 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE NO 23: GLASGOW COMA SCALE VS SERUM ALBUMIN 
GLASGOW COMA SCALE 
SERUM ALBUMIN 
MEAN SD 
MILD 4.23 0.18 
MODERATE 3.83 0.62 
SEVERE 3.15 0.66 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE NO 24: TYPE OF LESION VS SERUM ALBUMIN 
TYPE OF LESION 
SERUM ALBUMIN 
MEAN SD 
MCA INFARCT 3.57 0.69 
MULTI INFARCT 3.8 0.49 
POST CIRCULATION STROKE 3.2 0.95 
LACUNAR INFARCT 3.5 0.9 
ANOVA 
P VALUE - 0.402 
NON SIGNIFICANT 
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TABLE NO 25: DISABILITY VS SSS SCORE 
 
DISABILITY (MRS SCORE) 
SCANDINAVIAN STROKE SCALE 
MEAN SD 
MILD 40.43 4.99 
MODERATE 25.13 7.11 
SEVERE 19.34 9.73 
DEATH 2.64 2.13 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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SUMMARY 
OBJECTIVE 
1. To study whether serum albumin is a good prognostic indicator of acute 
ischemic stroke using modified rankin scale at 3 months follow up of 
patients admitted in general medicine ward, Coimbatore medical college 
hospital. 
2.  To identify other clinical and biochemical factors affecting the 
prognosis of acute ischemic stroke as measured by modified rankin scale 
at 3 months follow up. 
METHODOLOGY 
Patients admitted with first instance of ischemic stroke prsenting within 
72 hours were screened and selected based on them satisfying the inclusion 
criteria after undergoing the customary investigations. 
Those falling under the exclusion criteria were filtered out to end up 
with a pool of 100 patients. 
Scandinavian stroke scale was used to assess the severity of stroke at the 
time of admission. 
Serum albumin was calculated at the time of admission. 
Functional status was assessed with the help of modified rankin scale at 
the end of 90 days, either by direct interview or over the phone. 
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Statistical analysis was carried out to find if there existed a statistically 
significant association between the serum albumin on admission and the 
functional status at 90 days. Other variables were also assessed for 
significance. 
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DISCUSSION 
 
Albumin is a molecule with multifaceted action on various systems in 
the body. Neuroprotective effects of albumin have been well documented in 
animal studies. Studies have been conducted in the western population 
regarding the usefulness of serum albumin as an indicator of prognosis in 
ischemic stroke. There are few Indian studies in this regard. 
In our study, 56% were male, and the ramainder female, in keeping with 
the other studies on stroke undertaken in our population 
Majority of patients were in the 51-60 year age group, constituting 24% 
of the total patients. The mean age of 57.66+12.4, the oldest being 85 years old 
the youngest 27 years. There was no corelation between the age and serum 
albumin. 
The major comorbidity that contributed to ishemic stroke in our study 
was systemic hypertension (57%), while diabetes constituted 27% of the total, 
while 18% had both. There was no significant association between serum 
albumin and comorbidities. 
The other riskfactors were coronary artery disease, dyslipidemia and 
rheumatic heart disease (RHD). RHD contributed to the majority of stroke less 
than 35 years. 
Smoking and alcohol intake was found in 32% of the subjects. 
96 
 
Majority of subjects had lesion in the MCA territory (52%) in keeping with the 
national and international studies. 
GCS  vs ALBUMIN 
The association between GCS and albumin was found to be significant(p 
value<0.05) using the anova test. The mean albumin in those with GCS>13 
was 4.23 mg/dl while those for GCS< 9 was 3.15 mg/dl. 
SSS AND ALBUMIN 
The association between SSS and albumin had a significant association 
with a p value<0.05. Hence proving that there was a positive corelation 
between the SSS score at admission and the serum albumin. The mean albumin 
in patients with mild impairment was 4.2 mg/dl, while in those with severe 
impairment was 3.34 mg/dl. 
MRS AND ALBUMIN 
Using anova test, the association between MRS and serum albumin had 
a p value<0.05 which was significant. Hence there was a negative correlation 
between serum albumin at admission with the MRS score at 90 days. The mean 
albumin level in subjects with mild diability was 4.2 mg/dl, as opposed to 3.31 
mg/dl in patients with severe disability, and 2.9 mg/dl in patients who died. The 
higher the serum albumin level, the lower the MRS score, hence better the 
outcome at 90 days. 
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SSS SCORE AND MRS SCORE 
There was a strong negative correlation between the SSS score at 
admission and the MRS score at 90 days. This entails that higher the SSS score, 
lower the MRS score hence more the disability at 90 days. 
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CONCLUSION 
• There was no significant association of serum albumin with either sex or 
age 
• Majority of subjects were in the 50-60 year age group 
• Hypertension and diabtetes were the major risk factors 
• Serum albumin has a significant association with the severity as well as 
the prognosis of stroke 
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DEPARTMENT OF GENERAL MEDICINE, COIMBATORE 
MEDICAL COLLEGE HOSPITAL 
     PROFORMA 
A STUDY OF SERUM ALBUMIN LEVEL AS A PROGNOSTIC 
INDICATOR OF ACUTE ISCHEMIC STROKE 
         CASE NO: 
NAME: 
AGE/SEX: 
IP NUMBER: 
ADDRESS: 
PHONE NUMBER: 
PRESENTING COMPLAINTS 
• WEAKNESS 
• GIDDINESS 
• SEIZURE 
• UNRESPONSIVENESS 
• UNSTEADINESS OF GAIT 
• DEVIATION OF ANGLE OF MOUTH 
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DURATION OF SYMPTOMS: 
H/O FEVER/TRAUMA 
PAST HISTORY 
• PRIOR STROKE 
• DIABETES MELLITUS 
• HYPERTENSION 
• CARDIAC DISEASES 
• EPILEPSY 
• TUBERCULOSIS 
TREATMENT HISTORY: 
FAMILY HISTORY: 
ADDICTIONS: 
VITALS: 
• PULSE-RATE AND RHYTHM 
• BLOOD PRESSURE 
• RESPIRATORY RATE 
• TEMPERATURE 
GENERAL EXAMINATION 
SYSTEMIC EXAMINATION 
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CENTRAL NERVOUS SYSTEM 
• HIGHER MENTAL FUNCTION: CONSCIOUSNESS 
    ORIENTATION 
    SPEECH 
• CRANIAL NERVES 
• MOTOR SYSTEM: TONE 
       POWER 
      REFLEXES 
• SENSORY SYSTEM 
• CEREBELLAR SIGNS 
• MENINGEAL SIGNS 
• GLASGOW COMA SCALE- E  V  M   TOTAL SCORE:    /15 
• SCANDINAVIAN STROKE SCALE SCORE: 
CARDIOVASCULAR SYSTEM 
• APEX BEAT 
• HEART SOUNDS 
• MURMURS 
RESPIRATORY SYSTEM 
• BREATH SOUNDS 
• ADDED SOUNDS 
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GASTROINTESTINAL SYSTEM 
• ANY TENDERNESS 
• LIVER SPAN 
• SHIFTING DULLNESS 
INVESTIGATIONS 
• COMPLETE HEMOGRAM 
• RANDOM BLOOD SUGAR 
• BLOOD UREA 
• SERUM CREATININE 
• LIVER FUNCTION TEST 
• LIPID PROFILE 
• SERUM PROTEINS: TOTAL: 
          ALBUMIN: 
• URINE ROUTINE EXAMINATION: ALBUMIN: 
         SUGAR: 
         CAST: 
         CELLS: 
• ECG: 
• CT- BRAIN: 
• MODIFIED RANKIN SCALE SCORE (ON THE 90TH DAY): 
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ANNEXURE-II 
 
CONSENT FORM (ENGLISH) 
 
I have come to know that Dr. M.MOHAMED FAIZAL BASHEER, 
Postgraduate in the Department of General Medicine is conducting a study on 
the topic, “A STUDY OF 100 CASES OF PANCYTOPENIA: A CLINICO-
HEMATOLOGICAL CORRELATION”. 
 I understand that  I will not have to suffer any harmful consequences as a 
result of the study nor will I have any financial constraints. It is understood that 
blood will be collected from me/bone marrow aspiration or trephine biopsy will 
be done for me for the purpose of conducting this study.  I also understand that 
I can withdraw myself from this study at any point of time and by doing so it 
will not affect my treatment in any manner. Understanding all these, I 
wholeheartedly agree to take part in this study. 
             
    Signature 
    Name of the patient: 
    Signature 
    Name of the doctor: 
    Place: 
    Date: 
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1 VANAJA 55 F Y N N S 1 5 4.2 6 6 DEATH 
2 SEETHALAKSHMI 70 F Y N N N 4 14 4.2 30 4 MODERATE 
3 BALASUBRAMANIAM 53 M Y Y C,D S 2 11 3.5 32 4 MODERATE 
4 THEVASUMANI 35 F N Y N N 2 5 4.3 10 5 SEVERE 
5 MANOHARAN 72 M Y N D S 1 9 3 14 5 SEVERE 
6 VISWANATHAN 66 M N N N N 1 6 2.5 4 6 DEATH 
7 KANDHASAMY 50 M Y N N L 2 12 4.4 26 4 MODERATE 
8 ASHOK 29 M N N R N 2 9 4.1 20 5 SEVERE 
9 ANMBROSE 55 M N N N S,L 1 5 3.6 2 6 DEATH 
10 CHELLAMUTHU 68 M Y N N N 1 7 2.7 12 6 DEATH 
11 RANGASAMY 72 M N Y D S 1 12 4.5 46 1 MILD 
12 VENU 60 M N N N N 2 13 4 48 2 MILD 
13 MURALIDHARAN 38 M N N D N 1 5 3 2 6 DEATH 
14 THANGAPANDI 63 M N N N N 1 15 4.2 49 1 MILD 
115 
 
15 SUBBAIAH 78 M Y N N S 1 9 4.7 15 4 MODERATE 
16 CHELAPPAN 47 M N N D N 1 9 3 15 5 SEVERE 
17 MANOHARI 55 F Y N N N 1 5 2.7 2 6 DEATH 
18 RAJAN 64 M Y N N L 1 8 3.4 10 5 SEVERE 
19 RAMIAH 68 M Y N D N 1 9 4 11 5 SEVERE 
20 KARUPPAN 65 M N N D N 1 14 4.3 42 3 MILD 
21 GUNASEELAN 40 M Y N N S 3 11 3.8 24 4 MODERATE 
22 SUBBAN 62 M Y N N N 1 12 3.4 44 2 MILD 
23 VASUNDHARA 60 F Y N N N 1 5 2.4 2 6 DEATH 
24 VANAJA 45 F N N N S 3 4 2.6 2 6 DEATH 
25 NETAJI 42 M N Y N N 1 9 4.1 15 4 MODERATE 
26 NAGAVALLI 52 F Y Y C,D N 1 6 4.7 16 5 SEVERE 
27 LAKSHMI 85 F Y N D N 1 9 4.2 31 4 MODERATE 
28 MASILLAMANI 46 M Y Y N L 4 5 2.8 2 6 DEATH 
29 PAPPATHY 60 F N Y N N 1 8 4 31 4 MODERATE 
30 CHINNAMANI 55 F Y Y N N 4 7 4.5 30 4 MODERATE 
31 PALANISAMY 60 M N N N S 4 12 4.4 41 2 MILD 
32 THIRUMAN 72 M N N N S 1 13 4.5 39 3 MILD 
33 ARUMUGAM 65 M Y Y C N 4 15 4.6 46 1 MILD 
34 PONNATHAL 52 F N N N L 4 8 3 15 5 SEVERE 
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35 POUNTHAI 55 F Y N N S 4 9 2.1 42 5 SEVERE 
36 CHANDRA 37 F N N N N 1 5 2.8 2 6 DEATH 
37 HASEENA 70 F N N N N 1 5 3.2 2 6 DEATH 
38 KALAVATHY 44 F Y N N N 1 6 3 2 6 DEATH 
39 PATHUMMA 80 F Y Y C,D N 2 9 3.1 41 5 SEVERE 
40 BABU 38 M Y N N S 4 6 3.6 2 6 DEATH 
41 AMSAVENI 39 F N Y N N 4 9 4.8 15 4 MODERATE 
42 VICTOR 56 M Y Y N S,L 1 5 3.4 2 6 DEATH 
43 AYSHABEEVI 80 F N N N N 1 5 2.6 2 6 DEATH 
44 MOHD YUSUF 72 M N N N S 1 10 4.1 40 3 MILD 
45 SARASWATHY  52 F Y N N N 1 9 4.1 16 4 MODERATE 
46 VAIRAMUTHU 43 M Y N N N 4 7 3.2 34 4 MODERATE 
47 VIVEKANAND 39 M Y N N L 4 12 4.6 33 4 MODERATE 
48 SURESH KUMAR 42 M N N N N 4 11 2.8 29 5 SEVERE 
49 PHILOMINA 65 F Y Y N N 4 9 4.5 39 1 MILD 
50 PHILIP 75 M Y N N N 4 7 3.3 19 5 SEVERE 
51 SULAIMAN 60 M Y N N N 1 6 3.4 14 5 SEVERE 
52 DHANDAPANI 60 M Y Y N N 1 5 2.6 2 6 DEATH 
53 BABU 43 M N Y N S 1 9 4 34 4 MODERATE 
54 MOORTHY 42 M N N N N 1 9 4.1 21 4 MODERATE 
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55 MURUGAN 50 M Y Y N N 4 8 3.9 20 4 MODERATE 
56 VALLIYAMMAL 72 M N N N N 3 5 2.2 2 6 DEATH 
57 MARATHAL 72 F Y Y C S 1 6 3.6 4 5 SEVERE 
58 ALAGIRI 45 M N N N N 1 9 4 10 5 SEVERE 
59 MUTHAIAH 75 M Y N N S 2 10 4.2 30 5 SEVERE 
60 PARVATHY 62 F Y N N N 2 12 4.2 36 4 MODERATE 
61 SUNDAR 42 M Y N N N 2 5 3 2 6 DEATH 
62 MANIKYAM 45 F Y N N N 1 5 2.8 2 6 DEATH 
63 VANALAKSHMI 47 F N N N N 1 11 4.1 29 3 MILD 
64 MARUTHACHALAM 80 M Y N N N 4 12 4.6 33 2 MILD 
65 VANI 62 F N N N N 2 9 3.6 20 5 SEVERE 
66 DURAISAMY 44 M N N N N 4 8 3.4 12 5 SEVERE 
67 PRATHEEKSHA 27 F N N R N 2 10 4.1 23 4 MODERATE 
68 JAHANGIR 66 M N N N S 1 11 4.2 29 3 MILD 
69 MADHUBALA 44 F N Y N N 1 9 3.7 20 4 MODERATE 
70 MUTHUSELVAN 56 M N N N N 2 9 3.8 15 4 MODERATE 
71 MANIVASAGAM 55 M N Y C N 4 5 2.6 2 6 DEATH 
72 SARANYA 45 F Y N N N 2 10 4 26 4 MODERATE 
73 ZUBEIDA 44 F Y Y N S 2 13 4.1 38 3 MILD 
74 KARUPPUSAMY 83 M Y N C S,L 4 9 3.1 14 5 SEVERE 
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75 SANKARAPPAN 60 M Y N N N 2 6 4 24 5 SEVERE 
76 SELVI 38 F N N D N 1 6 3.4 14 5 SEVERE 
77 KARUPASAMY 64 M Y N N N 1 10 3.1 30 4 MODERATE 
78 KANDHASAMY 48 M Y Y N N 1 13 4.2 39 3 MILD 
79 SUBBULAKSHMI 58 F Y N N N 1 9 3.1 32 5 SEVERE 
80 MANOHARI 83 F Y Y C S 4 5 2.4 2 6 DEATH 
81 PAPPATHY 85 F Y N N N 1 6 2.1 4 5 SEVERE 
82 KALIAMMAL 60 F Y Y N N 4 4 2.2 2 6 DEATH 
83 KALPANA 41 F Y N N N 1 12 4 41 3 MILD 
84 KUMAR 39 M Y N N S 1 7 3.7 24 5 SEVERE 
85 SABIYABEE 66 F N N N S 3 9 4.2 21 4 MODERATE 
86 MANORANJITHAM 76 F Y N N N 1 11 2.8 29 5 SEVERE 
87 PASUPATHY 60 M N N N N 2 5 3 2 6 DEATH 
88 DEVASENA 45 F N Y N N 4 8 2.1 30 5 SEVERE 
89 KANNAMAL 82 F Y N N S 4 12 4.6 40 3 MILD 
90 BINDU 57 F Y Y N N 1 14 4.4 41 3 MILD 
91 MANICKAM 85 M Y N N S 1 12 4.1 39 3 MILD 
92 LAKSHMI 40 F N N N N 4 12 4 41 3 MILD 
93 NANJAMMAL 70 F Y N N N 1 10 3 16 5 SEVERE 
94 PAPPATHY 66 F N N N N 2 4 4 2 6 DEATH 
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95 VENDA 72 F Y Y N N 1 14 4.5 43 2 MILD 
96 JOSEPH 75 M N N N L 1 5 2.7 2 6 DEATH 
97 SANKAR 60 M N N N N 2 9 2.8 18 5 SEVERE 
98 RANGAMMAL 65 F Y N N N 4 6 3 24 5 SEVERE 
99 AMSAVENI 38 F N N N N 1 15 4.2 42 2 MILD 
100 BALASUBRAMANIAM 67 M Y Y N S 2 13 4.1 41 2 MILD 
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KEY TO MASTER CHART 
1- MCA  INFARCT 
2- MULTI-INFARCT 
3- PCA/POSTERIOR CIRCULATION STROKE 
4- LACUNAR STROKE 
C- CORONARY ARTERY HEART DISEASE 
D-DYSLIPIDEMIA 
R-RHEUMATIC HEART DISEASE 
S-SMOKING 
L-ALCOHOL 
Y-YES 
N-NIL 
SEVERITY 
GRADING 
MILD MODERATE SEVERE DEATH 
MRS 0-3 4 5 6 
SSS 43-58 26-42 0-25 - 
 
